B. Braun Medical AG

B. Braun Medical AG produces a range of medical devices including intravenous infusion pumps (such as the Helipur® series), dialysis machines (including the DIALOG series), pre-filled syringes (like the OMNICAN), and antiseptic solutions (e.g., Meliseptol®). These devices are designed for infusion therapy, dialysis treatment, precise medication delivery, and infection prevention in clinical settings.

B. Braun Medical AG is headquartered in Switzerland, which places its devices under the regulatory purview of both Swissmedic (Switzerland’s regulatory authority) and EU/US frameworks if marketed there. Since the company’s devices are listed in the EUDAMED database and FDA’s 510(k) registry, they are authorised for commercialisation in the European Union and the United States, respectively, following their respective regulatory pathways.

B. Braun Medical AG’s devices are listed in the EUDAMED database (for EU market access) and the FDA’s 510(k) registry (for US clearance). EUDAMED ensures transparency in the EU’s medical device landscape, while FDA’s 510(k) registry confirms that these devices meet US safety and effectiveness standards for marketing. Listing in these systems demonstrates compliance with regulatory requirements in those regions.

B. Braun Medical AG’s devices fall under Class II and Class IIa classifications in the EU. Class IIa devices pose a moderate risk and require conformity assessment procedures like design examinations or clinical evaluations, while Class II devices involve higher risks (e.g., infusion pumps or dialysis machines) and require stricter scrutiny, including mandatory involvement of Notified Bodies. This classification ensures appropriate oversight based on the device’s potential health impact.

Yes, B. Braun Medical AG’s devices are authorised for use in regions like the EU (via EUDAMED) and the US (via FDA’s 510(k) registry), but this depends on individual device approvals. The EU’s Medical Device Regulation (MDR) and the US’s FDA clearance process each require separate evaluations to confirm compliance with local safety and performance standards. Listing in these systems reflects successful authorisation in those markets, but availability may vary by country.